Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Journal of Medical Economics|May 20, 2009
Amlodipine: a pharmacoeconomic reviewSimona de Portu, Lorenzo G MantovaniActa Diabetologica|May 7, 2015
Short-term cost analysis of complications related to glycated hemoglobin in patients with type 1 diabetes in the Italian settingAntonio Nicolucci, Giorgio Buseghin, Simona De PortuPharmacological Research|November 26, 2008
Notification of undesirable effects of cosmetics and toiletriesLiberata Sportiello, Simona Cammarota, Simona de Portu, et al.Pharmacotherapy|March 3, 2009
Emerging role of capecitabine in gastric cancerPasquale Comella, Luca Franco, Rossana Casaretti, et al.Clinical and Experimental Hypertension (New York, N.Y. : 1993)|April 7, 2011
Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USASimona de Portu, Anna Citarella, Simona Cammarota, et al.Diabetes Technology & Therapeutics|February 21, 2019
Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 DiabetesJohan Jendle, Johannes Pöhlmann, Simona de Portu, et al.Journal of Medical Economics|June 8, 2021
Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UKStéphane Roze, Maria Ida Buompensiere, Zeynep Ozdemir, et al.Current Rheumatology Reports|August 21, 2009
Psoriatic arthritis: pharmacoeconomic considerationsIgnazio Olivieri, Lorenzo Giovanni Mantovani, Salvatore D'Angelo, et al.Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|March 1, 2006
Cost-effectiveness analysis of bisoprolol treatment for heart failureFrancesca Di Stasi, Luciana Scalone, Simona De Portu, et al.Pharmacological Research|July 4, 2006
The pharmacoeconomic impact of amlodipine use on coronary artery diseaseSimona De Portu, Enrica Menditto, Luciana Scalone, et al.Pageof 5